Bispecific Antibody Market Analysis

Bispecific Antibody Segmentation

Indication (Autoimmune Diseases, Oncology)

The oncology segment in the bispecific antibody market is poised to have the largest revenue share of about 65% till 2037. The rise in the development of therapies for cancer is expected to drive the segment’s gain. Since 2000, the number of cancer-targeting clinical studies has nearly quadrupled, rising from 421 in 2000 to 1,489 in 2021. Furthermore, the cases of cancer are predicted to rise in coming years, owing to the obese and unhealthy lifestyle of humans. Excess body weight is responsible for roughly 5% of new cancer cases in men and 10% in women each year. Bispecific antibodies can be combined with targeted agents, such as small molecule inhibitors or monoclonal antibodies, to achieve synergistic effects. By simultaneously targeting tumor cells and specific signaling pathways or growth factor receptors, bispecific antibodies in combination with targeted agents can enhance the anti-cancer activity and overcome resistance mechanisms, improving treatment outcomes.

End-Users (Homecare, Hospitals, Specialty Clinics)

The hospital segment in the bispecific antibody market will accumulate a significant portion of around 46% in the year 2037. Around 25% of patients died in a hospital in the United States, with 62% having been admitted at least once in the previous month. Furthermore, in their last and critical time of life, 29% of patients had been taken to an intensive care unit. They can target specific cancer cells while simultaneously engaging the immune system to enhance anti-tumor immune response. Bispecific antibodies can be administered as part of immunotherapy regimens, such as immune checkpoint inhibitors or CR-T cell therapies, to improve treatment outcomes and patient responses at hospitals.

Our in-depth analysis of the global bispecific antibody market includes the following segments: